About this Video

• Video Title: Vidofludimus Calcium for MS
• Channel: Dr. Brandon Beaber
• Speakers: Dr. Brandon Beaber
• Duration: 00:17:59

Introduction

This video discusses the investigational multiple sclerosis (MS) drug, vidofludimus calcium. Dr. Beaber reviews phase 2 trial results, exploring its effectiveness in relapsing and progressive MS, and potential side effects. He also delves into the drug's mechanisms of action and compares it to other MS treatments.

Key Takeaways

• Vidofludimus calcium's dual mechanism: It inhibits DHODH (similar to Aubagio) and activates NURR1, potentially offering both anti-inflammatory and neuroprotective effects.
• Phase 2 trial results (relapsing MS): The 30mg and 45mg doses showed significant reduction in active lesions. Relapse rates were slightly lower in the treatment groups but not statistically significant. Disability progression was not significantly different, though higher doses showed stability.
• Phase 2 trial results (progressive MS): A 20% reduction in disability progression was observed compared to placebo, with a more pronounced effect (30% reduction) in primary progressive MS. Brain atrophy reduction was not statistically significant (5%). Midpoint analysis showed a 22% reduction in neurofilament light chain in the treatment group.
• Side effects: Generally similar to placebo. Rare serious adverse events were reported, mainly in the higher-dose group. Liver enzyme elevations occurred, resolving upon discontinuation.
• Overall: While phase 2 results are promising, particularly in progressive MS, further research (phase 3 trials) is needed to confirm efficacy and safety. The drug's effect on disability progression, rather than solely on imaging markers, is highlighted as crucial.

The doctor presents a cautiously optimistic sentiment. While acknowledging that the phase 2 trial results, particularly in progressive MS, are promising (showing a reduction in disability progression), he emphasizes the need for phase 3 trials to confirm these findings. He highlights that a significant reduction in disability progression in older patients with progressive MS, even with a moderate reduction and low side effects, would still be valuable. However, he also expresses some skepticism regarding the role of the NURR1 receptor and points out the negative reaction to the Caliper trial press release, suggesting some uncertainty about its overall success. Therefore, it's not definitively labeled as a "winner" or "serious issue" but rather a medication with potential that requires further investigation.